674 results on '"Takashi Oshima"'
Search Results
52. Incidence and Risk of Venous Thromboembolism in Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy
- Author
-
MARIKO KAMIYA, SHINNOSUKE KAWAHARA, YUTO KAMIOKA, MASAAKI MURAKAWA, TORU AOYAMA, SATOSHI KOBAYASHI, MAKOTO UENO, NAOTO YAMAMOTO, TAKASHI OSHIMA, NORIO YUKAWA, YASUSHI RINO, MUNETAKA MASUDA, and SOICHIRO MORINAGA
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2023
53. Clinical Significance of Neutrophil-to-Lymphocyte Ratio/Serum Albumin Ratio in Patients With Metastatic Gastric or Gastroesophageal Junction Cancer Administered Trifluridine/Tipiracil
- Author
-
ITARU HASHIMOTO, KAZUKI KANO, SHIZUNE ONUMA, HIDEAKI SUEMATSU, SHINSUKE NAGASAWA, KYOHEI KANEMATSU, KYOKO FURUSAWA, TOMOMI HAMAGUCHI, MAMORU WATANABE, KEI HAYASHI, MITSUHIRO FURUTA, YASUHIRO INOKUCHI, NOZOMU MACHIDA, TORU AOYAMA, TAKANOBU YAMADA, YASUSHI RINO, TAKASHI OGATA, and TAKASHI OSHIMA
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2023
54. Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
- Author
-
Kohei Shitara, Motohiro Hirao, Satoru Iwasa, Takashi Oshima, Yoshito Komatsu, Akihito Kawazoe, Yasuyoshi Sato, Takuya Hamakawa, Kan Yonemori, Nozomu Machida, Satoshi Yuki, Takuya Suzuki, Shiori Okumura, Takao Takase, Taro Semba, Bob Zimmermann, Angela Teng, and Kensei Yamaguchi
- Subjects
Cancer Research ,Oncology - Abstract
Purpose: In the dose-expansion part of this open-label, phase I study, we explored the efficacy and safety of E7389-LF (liposomal formulation of eribulin) in Japanese patients with advanced gastric cancer. Patients and Methods: Patients with advanced gastric cancer who had been previously treated with ≥2 lines of chemotherapy received E7389-LF 2.0 mg/m2 every 3 weeks (the previously determined maximum tolerated dose, the primary objective of Study 114). Secondary objectives included objective response rate (ORR), progression-free survival (PFS), and safety; exploratory objectives included disease control rate (DCR) and clinical benefit rate (CBR), as well as pharmacodynamic measurements of serum biomarkers. Results: As of June 24, 2021, 34 patients were enrolled and treated (10 from the original dose-expansion cohort, expanded to include 24 additional patients). Six patients had partial responses, for an ORR of 17.6% [95% confidence interval (CI), 6.8–34.5], and the median PFS was 3.7 months (95% CI, 2.7–4.8). The DCR was 79.4% (95% CI, 62.1–91.3), and the CBR was 32.4% (95% CI, 17.4–50.5). Overall, 32 patients (94.1%) experienced treatment-related adverse events, and 26 patients (76.5%) experienced grade ≥3 events, most commonly neutropenia (41.2%) and leukopenia (29.4%). Of the 8 endothelial cell/vasculature markers tested in this study, 7 were significantly increased among patients treated with E7389-LF; these changes were generally consistent regardless of best overall response. Conclusions: E7389-LF 2.0 mg/m2 every 3 weeks was tolerable and showed preliminary activity for the treatment of patients with gastric cancer.
- Published
- 2023
55. A 0.11mm2 164dB-FOM 0.18μm CMOS pipelined ADC with novel passive amplification.
- Author
-
Takashi Oshima, Taizo Yamawaki, and Koji Maeda
- Published
- 2017
- Full Text
- View/download PDF
56. A 1200×1200 8-Edges/Vertex FPGA-Based Motion-Planning Accelerator for Dual-Arm-Robot Manipulation Systems.
- Author
-
Atsutake Kosuge and Takashi Oshima
- Published
- 2020
- Full Text
- View/download PDF
57. Carbon Ion RadiotherapyVersusPerioperative Adjuvant Chemotherapy and Curative Surgery for Resectable Pancreatic Cancer
- Author
-
NAOTO YAMAMOTO, TAKASHI OSHIMA, SHINNOSUKE KAWAHARA, DAISHI TAKAHASHI, YUTO KAMIOKA, MASAAKI MURAKAWA, HIROYUKI KATOH, MAKOTO UENO, and SOICHIRO MORINAGA
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2023
58. The Latest Treatments for Cancer Cachexia: An Overview
- Author
-
HAYATO WATANABE and TAKASHI OSHIMA
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2023
59. Clinical Course of Vitamin B12 Deficiency and Associated Risk Factors in Patients After Total Gastrectomy for Gastric Cancer
- Author
-
TORU AOYAMA, KENTARO HARA, YUKIO MAEZAWA, KEISUKE KAZAMA, ITARU HASHIMOTO, SHO SAWAZAKI, KEISUKE KOMORI, HIROSHI TAMAGAWA, AYAKO TAMAGAWA, KAZUKI KANO, HARUHIKO CHO, JUNYA MORITA, KENKI SEGAMI, MIE ISHIMOTO, TAKASHI OSHIMA, NORIO YUKAWA, and YASUSHI RINO
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2023
60. Should the splenic hilar lymph node be dissected for the management of adenocarcinoma of the esophagogastric junction?
- Author
-
Yuta Kumazu, Shinichi Hasegawa, Tsutomu Hayashi, Takanobu Yamada, Hayato Watanabe, Kentaro Hara, Yota Shimoda, Masato Nakazono, Shinsuke Nagasawa, Yasushi Rino, Munetaka Masuda, Takashi Ogata, Takashi Oshima, and Takaki Yoshikawa
- Subjects
Oncology ,Surgery ,General Medicine - Abstract
Splenic hilar lymphadenectomy is not recommended for advanced proximal gastric cancer that does not invade the greater curvature according to the results of the previous studies. The efficacy of splenic hilar lymphadenectomy for type II and type III adenocarcinomas of the esophagogastric junction and easy spread to the greater curvature of the stomach remains unclear. This study aimed to investigate the efficacy of splenic hilar lymphadenectomy and identify the risk factors for metastasis to splenic hilar nodes.We examined patients who underwent R0/1 gastrectomy for Siewert types II and III at a single high-volume center in Japan. We analyzed the metastatic incidence, therapeutic value index, and risk factors for splenic hilar lymph node metastasis.We examined 126 patients (74, type II; 52, type III). Splenectomy was performed in 76 patients. Metastatic incidence and the therapeutic value index of splenic hilar lymph nodes in patients with type II and type III tumors were 4.5% and 0, and 21.9% and 9.4, respectively. In the patients who underwent splenectomy, we identified Siewert type III tumors (odds ratio: 6.93, 95% confidence interval: 1.24-38.8, p = 0.027) and tumor location other than the lesser curvature (odds ratio: 7.36, 95% confidence interval: 1.32-41.1, p = 0.023) to be independent risk factors. The metastatic incidence (46.2%) and therapeutic value index (15.4) were high in patients with both risk factors.Splenic hilar lymphadenectomy may contribute to the survival of patients with Siewert type III tumors, especially when the predominant location is not the lesser curvature.
- Published
- 2023
61. Association of longer telomere length in cancer cells and cancer-associated fibroblasts with worse prognosis
- Author
-
Yoko Matsuda, Juanjuan Ye, Keiko Yamakawa, Yuri Mukai, Kazuki Azuma, Linxuan Wu, Kenkichi Masutomi, Taro Yamashita, Yataro Daigo, Yohei Miyagi, Tomoyuki Yokose, Takashi Oshima, Hiroyuki Ito, Soichiro Morinaga, Takeshi Kishida, Toshinari Minamoto, Motohiro Kojima, Shuichi Kaneko, Reiji Haba, Keiichi Kontani, Nobuhiro Kanaji, Keiichi Okano, Mariko Muto-Ishizuka, Masanao Yokohira, Kousuke Saoo, Katsumi Imaida, and Futoshi Suizu
- Subjects
Cancer Research ,Oncology - Abstract
Background Telomere dysfunction has been reported to be directly involved in carcinogenesis owing to chromosomal instability and immortalization; however, the clinicopathological significance of telomeres remains controversial. We have shown that telomere shortening occurs in normal-appearing duct cells at initiation and then continues during the progression of pancreatic cancer. In this study, we determined the clinicopathological and prognostic value of telomere length (TL) in cancer progression. Methods TL in both cancer cells and cancer-associated fibroblasts (CAFs) was analyzed by high-throughput quantitative fluorescence in situ hybridization using a previously reported cohort comprising 1434 cases of adenocarcinoma (ADC), squamous cell carcinoma (SCC), adenosquamous carcinoma, hepatocellular carcinoma, and renal cell carcinoma (RCC), which are known cancers with a statistically significantly low incidence of alternative lengthening of telomeres. Cases were divided into 2 groups as follows: longer and shorter telomeres, according to the median TL of cancer cells and CAFs. The statistical significance of TL in cancer cells and CAFs on clinicopathological characteristics and prognosis was analyzed. Results There was a close association between TL in cancer cells and CAFs. Longer telomeres in cancer cells and CAFs were associated with aggressive features such as advanced stage, high mitosis score and nuclear score, poorly differentiated cancer, and desmoplastic stroma in ADC. Furthermore, a longer TL was an independent prognostic factor for ADC, SCC, and RCC. Conclusions Longer telomeres are associated with worse prognosis in ADC, SCC, and RCC. Thus, TL is a novel biomarker for the diagnosis of aggressive cancers with poor prognoses.
- Published
- 2022
62. Clinical Significance ofSEC11AExpression in Patients With Locally Advanced Gastric Cancer
- Author
-
HIDEAKI SUEMATSU, KENTARO SAKAMAKI, NAOHIDE OUE, YUKIHIKO HIROSHIMA, YAYOI KIMURA, SHIZUNE ONUMA, ITARU HASHIMOTO, SHINSUKE NAGASAWA, TORU AOYAMA, TAKANOBU YAMADA, HIROSHI TAMAGAWA, TAKASHI OGATA, YASUSHI RINO, MUNETAKA MASUDA, WATARU YASUI, YOHEI MIYAGI, and TAKASHI OSHIMA
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2022
63. Foreword.
- Author
-
Takashi Oshima
- Published
- 2021
- Full Text
- View/download PDF
64. The Clinical Impact of Other Primary Cancer in Patients Who Received Curative Treatment for Esophageal Cancer
- Author
-
Toru, Aoyama, Yukio, Maezawa, Kentaro, Hara, Miwha, Ju, Keisuke, Komori, Hiroshi, Tamagawa, Ayako, Tamagawa, Keisuke, Kazama, Sho, Sawazaki, Itaru, Hashimoto, Kazuki, Kano, Haruhiko, Cho, Junya, Morita, Kenki, Segami, Tetsushi, Ishiguro, Tsutomu, Sato, Takashi, Oshima, Norio, Yukawa, and Yasushi, Rino
- Subjects
Neoplasms, Multiple Primary ,Survival Rate ,Cancer Research ,Esophageal Neoplasms ,Oncology ,Humans ,Neoplasms, Second Primary ,General Medicine ,Prognosis ,Retrospective Studies - Abstract
The present study evaluated the clinical impact of other metachronous or synchronous primary cancer (OPC) in patients who received curative treatment for esophageal cancer.The present study included 168 patients who underwent curative treatment for esophageal cancer between 2005 and 2018. Prognosis and differences between the OPC status (metachronous/synchronous) and clinic pathological parameters was analyzed.A total of 168 patients were included in this study. Forty patients were diagnosed with metachronous/synchronous OPC. When comparing the clinicopathological factors between the patients with and without OPC, the patients' background and postoperative clinical courses were very similar between the two groups. The 3- and 5-year overall survival rates in patients with esophageal cancer with OPC were 66.0% and 54.5%, respectively, while those in patients without OPC were 50.1% and 41.4%, respectively. There was no statistically significant difference in these rates (p=0.156). The OPC status was not included in the final multivariate analysis model.The OPC status was not found to be a prognostic factor for patients who received curative treatment for esophageal cancer. Therefore, it is not necessary to avoid performing curative treatment for esophageal cancer because of a patient's OPC status.
- Published
- 2022
65. Clinical Impact of Surgical Sarcopenia on Long-term Survival
- Author
-
Keisuke, Komori, Kazuki, Kano, Toru, Aoyama, Kentaro, Hara, Shinsuke, Nagasawa, Masato, Nakazono, Yota, Shimoda, Yukio, Maezawa, Yuta, Kumazu, Taiichi, Kawabe, Masakatsu, Numata, Tsutomu, Hayashi, Takanobu, Yamada, Hiroshi, Tamagawa, Tsutomu, Sato, Haruhiko, Cho, Norio, Yukawa, Yasushi, Rino, Takaki, Yoshikawa, Takashi, Ogata, and Takashi, Oshima
- Subjects
Sarcopenia ,Cancer Research ,Postoperative Complications ,Oncology ,Gastrectomy ,Risk Factors ,Stomach Neoplasms ,Humans ,General Medicine ,Neoplasm Recurrence, Local ,Muscle, Skeletal ,Prognosis ,Retrospective Studies - Abstract
Preoperative sarcopenia is associated with various cancers and affects the long-term prognosis of patients. After gastrectomy for gastric cancer, dynamic changes in body composition occur, and sarcopenia becomes more apparent after surgery than before surgery. However, the relationship between sarcopenia in the early postoperative period and long-term survival is not fully understood. The aim of this study was to determine the effects of surgical sarcopenia on long-term outcomes of patents with gastric cancer.We included 408 patients who underwent curative gastrectomy (distal or total gastrectomy) for gastric cancer at the Kanagawa Cancer Center from December 2013 to November 2017. Sarcopenia was defined using the skeletal muscle index (SMI), using computed tomography (CT) one month after gastrectomy. We compared the long-term outcomes between patients with and without sarcopenia.The 5-year overall survival (OS) rates were 83.2% and 91.4% in the surgical and non-surgical sarcopenia groups, respectively. The hazard ratio (HR) of surgical sarcopenia for OS was 2.410 (95% confidence interval (CI)=1.321-4.396). In addition, surgical sarcopenia was associated with non-cancer-related deaths and deaths from other cancers.Patients with surgical sarcopenia after gastrectomy should be carefully monitored not only for gastric cancer recurrence but also for the occurrence of other diseases, including other cancers.
- Published
- 2022
66. Effect of Preoperative Gastric Shape on Loss of Lean Body Mass After Distal Gastrectomy.
- Author
-
SHINSUKE NAGASAWA, MIE TANABE, SHIZUNE ONUMA, JUNYA MORITA, ITARU HASHIMOTO, HIDEAKI SUEMATSU, TORU AOYAMA, TAKANOBU YAMADA, TAKASHI OGATA, NORIO YUKAWA, YASUSHI RINO, AYA SAITO, and TAKASHI OSHIMA
- Subjects
LEAN body mass ,GASTRECTOMY ,STOMACH cancer ,ADJUVANT chemotherapy ,DISEASE incidence - Abstract
Background/Aim: Based on gastric shape, patients with gastric cancer can be divided into storage (hook-shaped and ptotic stomach) and reverse outflow (steerhorn and cascade stomach) groups. In patients with gastric cancer, postoperative loss of lean body mass (LBM) is associated with a poor prognosis. This study investigated the influence of preoperative gastric shape on LBM loss 1 month after curative distal gastrectomy. Patients and Methods: Between May 2011 and May 2019, we enrolled 487 patients with pathological stage IA/IB/IIA gastric cancer who underwent curative distal gastrectomy and did not receive adjuvant chemotherapy. Patients were divided into storage (n=370) and outflow (n=117) groups according to whether barium was stored in the stomach during the preoperative fluoroscopic examination. Clinicopathological features, LBM 1 month after gastrectomy, and predictors of postoperative LBM loss were compared between the groups using multivariable logistic regression. Results: The incidence of >5% LBM loss and >7.5% body weight loss 1 month postoperatively were significantly higher in the storage group than in the outflow group (p=0.003 and p=0.009, respectively). Multivariable analysis revealed that gastric shape [odds ratio (OR)=3.30, 95% confidence interval (CI)=1.95-5.59, p<0.001], male sex (OR=3.20, 95% CI=2.07-4.96, p<0.001), and Roux-en-Y reconstruction (OR=1.69, 95% CI=1.08-2.64, p=0.02) were independent predictors of LBM loss. Postoperative dietary problems, especially dumping syndrome, diarrhea, and reflux were more common in the storage group (p<0.001). Conclusion: Gastric shape may be a useful independent predictor of postoperative LBM loss in patients with gastric cancer undergoing distal gastrectomy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
67. Clinical Significance of Prealbumin Level Measurement Before Neoadjuvant Chemotherapy in Elderly Patients With Locally Advanced Esophageal Cancer.
- Author
-
HIDEAKI SUEMATSU, TAKANOBU YAMADA, SHIZUNE ONUMA, ITARU HASHIMOTO, KYOHEI KANEMATSU, SHINSUKE NAGASAWA, TORU AOYAMA, TAKASHI OGATA, YASUSHI RINO, AYA SAITO, and TAKASHI OSHIMA
- Subjects
NEOADJUVANT chemotherapy ,ESOPHAGEAL cancer ,TRANSTHYRETIN ,ESOPHAGECTOMY ,OLDER patients - Abstract
Background/Aim: Radical esophagectomy after preoperative neoadjuvant chemotherapy (NAC) is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC). However, careful treatment selection is required when considering organ function in elderly patients. Prealbumin, a rapid turnover protein, is a short-term dynamic nutritional index, and its relationship with long-term postoperative survival in various cancers has been previously reported. However, the association between serum prealbumin level before NAC and survival in elderly patients remains unclear. This study investigated the clinical significance of prealbumin level measurement before NAC in elderly patients with locally advanced ESCC who underwent surgery after NAC. Patients and Methods: Eighty patients aged =65 years diagnosed with cStage II/III ESCC and undergoing radical esophagectomy after cisplatin and 5-fluorouracil therapy as NAC, were included. The cutoff value of the serum prealbumin level before NAC was set at 18.2 mg/dl using receiver operating characteristic curve analysis, and postoperative complications, recurrence, and overall survival were compared between the low and high prealbumin groups. Results: There were no differences in patient background, clinicopathological characteristics, postoperative complications, or recurrence-free survival between the two groups. Overall survival (OS) was significantly worse in the low prealbumin group than in the high prealbumin group (5-year survival, 33.3% vs. 67.0%; p=0.0341). Furthermore, on univariate and multivariate analysis, low prealbumin level was an independent poor OS factor (p=0.036). Conclusion: In elderly patients with locally advanced ESCC, serum prealbumin level before NAC may be a useful prognostic factor and may be important in selecting a treatment strategy that considers individual organ function. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
68. Significance of Preoperative Modified Nutritional Risk Index in Patients With Gastric Cancer After Curative Resection.
- Author
-
HAYATO WATANABE, ITARU HASHIMOTO, MIE TANABE, SHIZUNE ONUMA, JUNYA MORITA, SHINSUKE NAGASAWA, KYOHEI KANEMATSU, TORU AOYAMA, TAKANOBU YAMADA, TAKASHI OGATA, YASUSHI RINO, AYA SAITO, and TAKASHI OSHIMA
- Subjects
STOMACH cancer ,SURGICAL excision ,SERUM albumin ,BODY mass index ,SURGICAL complications - Abstract
Background/Aim: A new modified nutritional risk index (mNRI), calculated using serum albumin (g/l)+body mass index (BMI) [weight (kg_/height² (m²)], is a good predictor of postoperative complications and cancer survival. However, no study has used this index in patients with gastric cancer (GC). Therefore, we aimed to investigate the clinical significance of the preoperative mNRI values in patients with GC who underwent curative resection. Patients and Methods: We examined 449 patients who underwent curative resection for GC at Kanagawa Cancer Center between 2013 and 2017. The mNRI cutoff value obtained using a receiver operating characteristic analysis was 23.31. Patients were divided into high and low mNRI groups according to the cutoff value, and the clinicopathological characteristics and outcomes were compared between the two groups. Results: In terms of clinicopathological characteristics, the high mNRI group had a higher proportion of men, higher BMI, and a higher proportion of patients with American Society of Anesthesiologists physical status class 2/3 compared with the low mNRI group; the low mNRI group had significantly worse 5-year recurrence-free survival (RFS) and overall survival (OS) than the high mNRI group (OS, p=0.005) (OS, p=0.006; RFS, p=0.018) did. In the multivariate analysis, a low mNRI was an independent predictor of OS (p=0.006) and RFS (p=0.013). Conclusion: Preoperative mNRI may be a useful recurrence and prognostic biomarker in patients with GC who have undergone curative resection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
69. The Clinical Impact of the Pretreatment Platelet-to-Lymphocyte Ratio in Gastric Cancer Patients Who Receive Curative Treatment.
- Author
-
TORU AOYAMA, ITARU HASHIMOTO, YUKIO MAEZAWA, KENTARO HARA, KEISUKE KAZAMA, MASAKATSU NUMATA, NATSUMI KAMIYA, HIROSHI TAMAGAWA, SHO SAWAZAKI, SHINNOSUKE KAWAHARA, KEISUKE KOMORI, AYAKO TAMAGAWA, HARUHIKO CHO, JUNYA MORITA, KAZUKI OTANI, AYA KATO, MIE TANABE, TAKASHI OSHIMA, NORIO YUKAWA, and AYA SAITO
- Subjects
STOMACH cancer treatment ,BLOOD platelets ,LYMPHOCYTES ,CLINICAL trials ,MULTIVARIATE analysis - Abstract
Background/Aim: The platelet-to-lymphocyte ratio (PLR) is a promising prognostic marker in some malignancies. The present study evaluated the clinical impact of the PLR in patients with gastric cancer who underwent curative resection. Patients and Methods: This study included 258 patients who underwent curative treatment for gastric cancer between 2005 and 2020. The prognosis and clinicopathological parameters between the high- and low- PLR statuses were analyzed. Results: The overall survival (OS) stratified by each clinical factor was compared using the log-rank test, and a significant difference was observed using a pretreatment PLR of 150. When comparing the patient backgrounds between the high-PLR (PLR≥150) and low-PLR (PLR<150) groups, there were no significant differences between the two groups. The OS rates at 3 and 5 years after surgery were significantly higher at 70.8% and 60.4%, respectively, for the high-PLR group than at 83.6% and 79.7%, respectively, for the low-PLR group. Univariate and multivariate analyses of the OS showed that the PLR was a significant prognostic factor. In addition, when comparing the first recurrence sites, there were significant differences in peritoneal recurrence. Conclusion: The PLR is a significant risk factor for gastric cancer, making it a promising prognostic factor for patients with gastric cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
70. 17-MS/s 9-bit cyclic ADC with gain-assisted MDAC and attenuation-based calibration.
- Author
-
Yuki Okada and Takashi Oshima
- Published
- 2015
- Full Text
- View/download PDF
71. Clinical Significance of EREG Gene Expression in Gastric Cancer Tissue After Curative Surgery
- Author
-
HIDEAKI SUEMATSU, ITARU HASHIMOTO, YUKIHIKO HIROSHIMA, HAYATO WATANABE, KAZUKI KANO, KOSUKE TAKAHASHI, TORU AOYAMA, TAKANOBU YAMADA, HIROSHI TAMAGAWA, TAKASHI OGATA, NORIO YUKAWA, YASUSHI RINO, MUNETAKA MASUDA, YOHEI MIYAGI, and TAKASHI OSHIMA
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2022
72. Feasibility and Safety of Oral Nutritional Supplementation with High-Density Liquid Diet After Total Gastrectomy for Gastric Cancer
- Author
-
Takanobu, Yamada, Tsutomu, Hayashi, Hirohito, Fujikawa, Yuta, Kumazu, Shinsuke, Nagasawa, Masato, Nakazono, Kazuki, Kano, Kentaro, Hara, Hayato, Watanabe, Keisuke, Komori, Yota, Shimoda, Kosuke, Takahashi, Takashi, Ogata, Takashi, Oshima, and Takaki, Yoshikawa
- Subjects
Gastrectomy ,Stomach Neoplasms ,Dietary Supplements ,Weight Loss ,Feasibility Studies ,Humans ,Surgery ,Diet - Abstract
Patients requiring total gastrectomy for gastric cancer experience a decrease in food intake leading to severe body weight loss after surgery. This loss may be prevented using a high-density liquid diet of high caloric content and minimal volume. This phase II study evaluated the feasibility and safety of a high-density liquid diet (UpLeadUpLeadAmong 35 patients enrolled before surgery between April 2018 and December 2019, 29 patients who could initiate UpLeadOral nutritional supplementation with a high-density liquid diet (UpLead
- Published
- 2022
73. A low 1/f-noise accelerometer frontend using chopper stabilization at a frequency matched with a notch of quantization noise.
- Author
-
Kazuo Ono, Daisuke Maeda, Takashi Oshima, Toshiaki Nakamura, Joan Giner, and Tomonori Sekiguchi
- Published
- 2016
- Full Text
- View/download PDF
74. A concentrated springs architecture for single-digit frequency symmetry in Si MEMS gyroscope.
- Author
-
Joan Giner, Yuhua Zhang, Takashi Shiota, Daisuke Maeda, Kazuo Ono, Shinya Kajiyama, Takashi Oshima, Taizo Yamawaki, and Tomonori Sekiguchi
- Published
- 2016
- Full Text
- View/download PDF
75. Supplementary Figure S5 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
- Author
-
Kensei Yamaguchi, Angela Teng, Bob Zimmermann, Taro Semba, Takao Takase, Shiori Okumura, Takuya Suzuki, Satoshi Yuki, Nozomu Machida, Kan Yonemori, Takuya Hamakawa, Yasuyoshi Sato, Akihito Kawazoe, Yoshito Komatsu, Takashi Oshima, Satoru Iwasa, Motohiro Hirao, and Kohei Shitara
- Abstract
Supplementary Figure S5 shows pharmacodynamic changes in biomarkers over time (A) and changes by best overall response (B) in all study 114 cohorts.
- Published
- 2023
76. Supplementary Table S3 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
- Author
-
Kensei Yamaguchi, Angela Teng, Bob Zimmermann, Taro Semba, Takao Takase, Shiori Okumura, Takuya Suzuki, Satoshi Yuki, Nozomu Machida, Kan Yonemori, Takuya Hamakawa, Yasuyoshi Sato, Akihito Kawazoe, Yoshito Komatsu, Takashi Oshima, Satoru Iwasa, Motohiro Hirao, and Kohei Shitara
- Abstract
Supplementary Table S3 provides a summary of infusion-related reactions during cycle 1, per premedication.
- Published
- 2023
77. Data from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
- Author
-
Kensei Yamaguchi, Angela Teng, Bob Zimmermann, Taro Semba, Takao Takase, Shiori Okumura, Takuya Suzuki, Satoshi Yuki, Nozomu Machida, Kan Yonemori, Takuya Hamakawa, Yasuyoshi Sato, Akihito Kawazoe, Yoshito Komatsu, Takashi Oshima, Satoru Iwasa, Motohiro Hirao, and Kohei Shitara
- Abstract
Purpose:In the dose-expansion part of this open-label, phase I study, we explored the efficacy and safety of E7389-LF (liposomal formulation of eribulin) in Japanese patients with advanced gastric cancer.Patients and Methods:Patients with advanced gastric cancer who had been previously treated with ≥2 lines of chemotherapy received E7389-LF 2.0 mg/m2 every 3 weeks (the previously determined maximum tolerated dose, the primary objective of Study 114). Secondary objectives included objective response rate (ORR), progression-free survival (PFS), and safety; exploratory objectives included disease control rate (DCR) and clinical benefit rate (CBR), as well as pharmacodynamic measurements of serum biomarkers.Results:As of June 24, 2021, 34 patients were enrolled and treated (10 from the original dose-expansion cohort, expanded to include 24 additional patients). Six patients had partial responses, for an ORR of 17.6% [95% confidence interval (CI), 6.8–34.5], and the median PFS was 3.7 months (95% CI, 2.7–4.8). The DCR was 79.4% (95% CI, 62.1–91.3), and the CBR was 32.4% (95% CI, 17.4–50.5). Overall, 32 patients (94.1%) experienced treatment-related adverse events, and 26 patients (76.5%) experienced grade ≥3 events, most commonly neutropenia (41.2%) and leukopenia (29.4%). Of the 8 endothelial cell/vasculature markers tested in this study, 7 were significantly increased among patients treated with E7389-LF; these changes were generally consistent regardless of best overall response.Conclusions:E7389-LF 2.0 mg/m2 every 3 weeks was tolerable and showed preliminary activity for the treatment of patients with gastric cancer.
- Published
- 2023
78. A 1-GS/s 11.5-ENOB time-interleaved ADC with fully digital background calibration.
- Author
-
Yohei Nakamura and Takashi Oshima
- Published
- 2014
- Full Text
- View/download PDF
79. The Systemic Inflammation Score Is an Independent Prognostic Factor for Esophageal Cancer Patients who Receive Curative Treatment
- Author
-
Toru, Aoyama, Mihwa, Ju, Keisuke, Komori, Hiroshi, Tamagawa, Ayako, Tamagawa, Yukio, Maezawa, Itaru, Hashimoto, Kazuki, Kano, Kentaro, Hara, Haruhiko, Cho, Kenki, Segami, Daisuke, Machida, Masato, Nakazono, Takashi, Oshima, Norio, Yukawa, and Yasushi, Rino
- Subjects
Inflammation ,Survival Rate ,Cancer Research ,Esophageal Neoplasms ,Oncology ,Humans ,General Medicine ,Prognosis - Abstract
Perioperative systemic inflammation affects the long-term oncological outcomes in cases of malignancies. We evaluated the clinical impact of the preoperative systemic inflammation score (SIS) in resectable esophageal cancer patients who received curative treatment.This study included 168 patients who underwent curative surgery followed by perioperative adjuvant chemotherapy for esophageal cancer between 2005 and 2018. The risk factors for overall survival (OS) and recurrence-free survival (RFS) were identified.Based on the 3- and 5-year OS rate, we set the cut-off value for SIS at 2 in the preset study. Among the 168 total patients, 119 were categorized as the Low-SIS group, and 49 were categorized as the High-SIS group. The respective 3- and 5-year OS rates were 61.9% and 52.4% in the Low-SIS group and 33.3% and 26.6% in the High-SIS group. There were significant differences in OS (p0.001). The SIS was therefore selected for the final multivariate analysis model (hazard ratio=2.094, 95% confidence interval=1.355-3.234, p0.001). On comparing the perioperative clinical course between the High- and Low-SIS groups, there were significant differences in the rate of postoperative anastomosis leakage of grade ≥2 between the groups (61.5% in the High-SIS group vs. 30.3% in the Low-SIS group; p=0.021).The systemic inflammation score had a clinical effect on the long-term oncological outcomes in esophageal cancer patients, suggesting that it might be a promising prognostic factor for esophageal cancer patients.
- Published
- 2022
80. Chemotherapy-induced Reversion of Mutant RAS to Wild-type RAS in Metastatic Colorectal Cancer
- Author
-
SUMITO SATO, YO MIKAYAMA, MANABU SHIOZAWA, SUGURU NUKADA, KENTA IGUCHI, HIRONAO OKAMOTO, TAKASHI KOHMURA, KEISUKE KAZAMA, KUNIYA TANAKA, TAKASHI OSHIMA, and YASUSHI RINO
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2022
81. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial
- Author
-
Jia Guan, Takaki Yoshikawa, Shiro Tanaka, Heike I. Grabsch, Yohei Miyagi, Yasushi Rino, Jeeyun Lee, Junichi Sakamoto, Nesaretnam Barr Kumarakulasinghe, Yiong Huak Chan, Takashi Oshima, Michal Marek Hoppe, Anand D. Jeyasekharan, Mark De Simone, Munetaka Masuda, Akira Tsuburaya, Kazuhiro Yoshida, Cedric Chuan Young Ng, Raghav Sundar, Angie Lay-Keng Tan, Patrick Tan, RS: GROW - R2 - Basic and Translational Cancer Biology, and Pathologie
- Subjects
Oncology ,medicine.medical_specialty ,Paclitaxel ,medicine.medical_treatment ,adjuvant treatment ,Adenocarcinoma ,THERAPY ,Disease-Free Survival ,Ramucirumab ,Machine Learning ,chemistry.chemical_compound ,CISPLATIN ,Stomach Neoplasms ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Stomach cancer ,UFT ,DOCETAXEL ,Chemotherapy ,business.industry ,gastric cancer ,Gastroenterology ,Cancer ,Gene signature ,CHEMOTHERAPY ,medicine.disease ,COMPREHENSIVE MOLECULAR CHARACTERIZATION ,TUMORS ,FAMILY ,Clinical trial ,chemistry ,Cohort ,5-FLUOROURACIL ,SENSITIVITY ,business - Abstract
ObjectiveTo date, there are no predictive biomarkers to guide selection of patients with gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional group Trial (SAMIT) was a 2×2 factorial randomised phase III study in which patients with GC were randomised to Pac-S-1 (paclitaxel +S-1), Pac-UFT (paclitaxel +UFT), S-1 alone or UFT alone after curative surgery.DesignThe primary objective of this study was to identify a gene signature that predicts survival benefit from paclitaxel chemotherapy in GC patients. SAMIT GC samples were profiled using a customised 476 gene NanoString panel. A random forest machine-learning model was applied on the NanoString profiles to develop a gene signature. An independent cohort of metastatic patients with GC treated with paclitaxel and ramucirumab (Pac-Ram) served as an external validation cohort.ResultsFrom the SAMIT trial 499 samples were analysed in this study. From the Pac-S-1 training cohort, the random forest model generated a 19-gene signature assigning patients to two groups: Pac-Sensitive and Pac-Resistant. In the Pac-UFT validation cohort, Pac-Sensitive patients exhibited a significant improvement in disease free survival (DFS): 3-year DFS 66% vs 40% (HR 0.44, p=0.0029). There was no survival difference between Pac-Sensitive and Pac-Resistant in the UFT or S-1 alone arms, test of interaction pConclusionUsing machine-learning techniques on one of the largest GC trials (SAMIT), we identify a gene signature representing the first predictive biomarker for paclitaxel benefit.Trial registration numberUMIN Clinical Trials Registry: C000000082 (SAMIT); ClinicalTrials.gov identifier, 02628951 (South Korean trial)
- Published
- 2022
82. Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab
- Author
-
Hideaki, Suematsu, Kazuki, Kano, Takanobu, Yamada, Itaru, Hashimoto, Hayato, Watanabe, Kosuke, Takahashi, Mamoru, Watanabe, Kei, Hayashi, Yoshihiro, Kaneta, Mitsuhiro, Furuta, Yasuhiro, Inokuchi, Nozomu, Machida, Toru, Aoyama, Hiroshi, Tamagawa, Norio, Yukawa, Yasushi, Rino, Munetaka, Masuda, Takashi, Ogata, and Takashi, Oshima
- Subjects
Adult ,Aged, 80 and over ,Male ,Cancer Research ,Time Factors ,General Medicine ,Middle Aged ,Progression-Free Survival ,Nivolumab ,Oncology ,Stomach Neoplasms ,Humans ,Female ,Neoplasm Metastasis ,Immune Checkpoint Inhibitors ,Aged ,Retrospective Studies - Abstract
To evaluate the impact of development of nivolumab monotherapy-induced immune-related adverse events (irAEs) and continuing nivolumab with irAEs on the survival of patients with gastric cancer (GC).Patients with unresectable advanced GC and recurrence after curative resection who received nivolumab monotherapy were included in the study. Survival was compared between patients who did and did not develop irAEs, and between those who continued and discontinued treatment due to irAEs.Of 110 GC patients, 22 developed irAEs. Grade ≥3 IrAEs included rash and diarrhoea associated with enteritis. Progression-free and overall survival (OS) were significantly better in patients with irAEs than in those without. The overall survival of patients who continued treatment despite irAEs was better than that of those who discontinued treatment.irAE development was associated with better survival in patients with GC who received nivolumab monotherapy. Continuing nivolumab with appropriate treatment in GC patients with irAEs may improve survival.
- Published
- 2022
83. Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma
- Author
-
Arnaldo N. S. Silva, Yuichi Saito, Takaki Yoshikawa, Takashi Oshima, Jeremy D. Hayden, Jan Oosting, Sophie Earle, Lindsay C. Hewitt, Hayley L. Slaney, Alex Wright, Imran Inam, Ruth E. Langley, William Allum, Matthew G. Nankivell, Gordon Hutchins, David Cunningham, Heike I. Grabsch, RS: GROW - R2 - Basic and Translational Cancer Biology, Pathologie, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy
- Subjects
Male ,Herpesvirus 4, Human ,ESOPHAGEAL ADENOCARCINOMA ,Gene Dosage ,PROTEIN ,Adenocarcinoma ,SUBTYPES ,Immunocompromised Host ,Stomach Neoplasms ,Chromosomal Instability ,Biomarkers, Tumor ,Humans ,INTEGRATED GENOMIC CHARACTERIZATION ,Aged ,Neoplasm Staging ,Retrospective Studies ,EXPRESSION-BASED CLASSIFICATION ,MISMATCH REPAIR DEFICIENCY ,MUTATIONS ,Middle Aged ,Genes, p53 ,Prognosis ,CANCER ,Mutation ,Female ,Surgery - Abstract
Background Patients with Epstein–Barr virus-positive gastric cancers or those with microsatellite instability appear to have a favourable prognosis. However, the prognostic value of the chromosomal status (chromosome-stable (CS) versus chromosomal instable (CIN)) remains unclear in gastric cancer. Methods Gene copy number aberrations (CNAs) were determined in 16 CIN-associated genes in a retrospective study including test and validation cohorts of patients with gastric cancer. Patients were stratified into CS (no CNA), CINlow (1–2 CNAs) or CINhigh (3 or more CNAs). The relationship between chromosomal status, clinicopathological variables, and overall survival (OS) was analysed. The relationship between chromosomal status, p53 expression, and tumour infiltrating immune cells was also assessed and validated externally. Results The test and validation cohorts included 206 and 748 patients, respectively. CINlow and CINhigh were seen in 35.0 and 15.0 per cent of patients, respectively, in the test cohort, and 48.5 and 20.7 per cent in the validation cohort. Patients with CINhigh gastric cancer had the poorest OS in the test and validation cohorts. In multivariable analysis, CINlow, CINhigh and pTNM stage III–IV (P < 0.001) were independently associated with poor OS. CIN was associated with high p53 expression and low immune cell infiltration. Conclusion CIN may be a potential new prognostic biomarker independent of pTNM stage in gastric cancer. Patients with gastric cancer demonstrating CIN appear to be immunosuppressed, which might represent one of the underlying mechanisms explaining the poor survival and may help guide future therapeutic decisions.
- Published
- 2022
84. Panel discussions: 'Challenges to the scaling limits: How can we achieve sustainable power-performance improvements?'.
- Author
-
Koji Inoue, Takuya Araki, Takumi Maruyama, Pritish Narayanan, Takashi Oshima, and Martin Schulz 0001
- Published
- 2018
- Full Text
- View/download PDF
85. A 4.8x Faster FPGA-Based Iterative Closest Point Accelerator for Object Pose Estimation of Picking Robot Applications.
- Author
-
Atsutake Kosuge, Keisuke Yamamoto, Yukinori Akamine, Taizo Yamawaki, and Takashi Oshima
- Published
- 2019
- Full Text
- View/download PDF
86. Feasibility of gastric endoscopic submucosal dissection in elderly patients aged ≥ 80 years
- Author
-
Yasuhiro, Inokuchi, Ayaka, Ishida, Kei, Hayashi, Yoshihiro, Kaneta, Hayato, Watanabe, Kazuki, Kano, Mitsuhiro, Furuta, Kosuke, Takahashi, Hirohito, Fujikawa, Takanobu, Yamada, Kouji, Yamamoto, Nozomu, Machida, Takashi, Ogata, Takashi, Oshima, and Shin, Maeda
- Subjects
Early gastric cancer ,Elderly ,Complications ,Retrospective Study ,Prognostic indicators ,Endoscopic submucosal dissection ,Charlson comorbidity index - Abstract
BACKGROUND Endoscopic resection, especially endoscopic submucosal dissection (ESD), is increasingly performed in elderly patients with early gastric cancer, and lesions beyond the expanded indications are also resected endoscopically in some patients. It is essential to assess whether gastric ESD is safe and suitable for elderly patients and investigate what type of lesions carry an increased risk of ESD-related complications. AIM To assess the efficacy and feasibility of gastric ESD for elderly patients, and define high-risk lesions and prognostic indicators. METHODS Among a total of 1169 sessions of gastric ESD performed in Kanagawa Cancer Center Hospital from 2006 to 2014, 179 sessions (15.3%) were performed in patients aged ≥ 80 years, and 172 of these sessions were done in patients with a final diagnosis of gastric cancer. These patients were studied retrospectively to evaluate short-term outcomes and survival. The short-term outcomes included the rates of en bloc resection and curative resection, complications, and procedure-related mortality. Curability was assessed according to the Japanese Gastric Cancer Treatment Guidelines 2010. Fisher’s exact test was used to statistically analyze risk factors. Clinical characteristics of each group were compared using Fisher’s exact test and Mann-Whitney U test. Survival rates at each time point were based on Kaplan-Meier estimation. Overall survival rates were compared between patients with gastric cancer in each group with use of the log-rank test. To identify prognostic factors that jointly predict the hazard of death while controlling for model overfitting, we used the least absolute shrinkage and selection operator (LASSO) Cox regression model including factors curative/ noncurative, age, gender, body mass index, prognostic nutritional index, Charlson comorbidity index (CCI), Glasgow prognostic score, neutrophil-to-lymphocyte ratio, and antithrombotic agent use. We selected the LASSO Cox regression model that resulted in minimal prediction error in 10-fold cross-validation. P < 0.05 was considered statistically significant. RESULTS The en bloc dissection rate was 97.1%, indicating that a high quality of treatment was achieved even in elderly patients. As for complications, the rates of bleeding, perforation and aspiration pneumonitis were 3.4%, 1.1% and 0.6%, respectively. These complication rates indicated that ESD was not associated with a particularly higher risk in elderly patients than in nonelderly patients. A dissection incision > 40 mm, lesions associated with depressions, and lesions with ulcers were risk factors for post-ESD bleeding, and location of the lesion in the upper third of the stomach was a risk factor for perforation in elderly patients (P < 0.05). Location of the lesion in the lower third of the stomach tended to be associated with a higher risk of bleeding. The overall survival (OS) did not differ significantly between curative and noncurative ESD (P = 0.69). In patients without additional surgery, OS rate was significantly lower in patients with a high CCI (≥ 2) than in those with a low CCI (≤ 1) (P < 0.001). CONCLUSION Gastric ESD is feasible even in patients aged ≥ 80 years. Observation without additional surgery after noncurative ESD is reasonable, especially in elderly patients with CCI ≥ 2.
- Published
- 2022
87. The Comparison of the Dietary Intake Loss Between Elderly and Non-Elderly Patients After Gastrectomy for Gastric Cancer
- Author
-
Masato, Nakazono, Toru, Aoyama, Keisuke, Komori, Hayato, Watanabe, Kazuki, Kano, Shinsuke, Nagasawa, Kenki, Segami, Hiroshi, Tamagawa, Norio, Yukawa, Yasushi, Rino, Takashi, Ogata, and Takashi, Oshima
- Subjects
Oncology ,Gastroenterology - Abstract
Background/Aim The present study quantified the changes in the dietary and nutritional intake after gastrectomy between elderly and non-elderly patients. Patients and Methods This prospective observational study enrolled patients who underwent curative gastrectomy for gastric cancer. Results Twenty-three patients ≥ 75 years old were classified into the elderly group, and 127 patients p = 0.075 and 0.080). On comparing the intake loss of three major nutrients, the respective median % lipid intake losses at 1 and 3 months postoperatively were −13.5% and −5.8% in the elderly group and −7.3% and 0% in the non-elderly group (p = 0.029 and 0.045). Conclusion Our results suggested that elderly patients experienced more serious lipid intake loss after gastrectomy than non-elderly patients.
- Published
- 2022
88. Clinical Significance of Mean Corpuscular Volume in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
- Author
-
Hayato, Watanabe, Kazuki, Kano, Itaru, Hashimoto, Hideaki, Suematsu, Toru, Aoyama, Takanobu, Yamada, Takashi, Ogata, Yasushi, Rino, and Takashi, Oshima
- Subjects
Erythrocyte Indices ,Pharmacology ,Cancer Research ,Esophageal Neoplasms ,Carcinoma, Squamous Cell ,Humans ,Esophageal Squamous Cell Carcinoma ,Prognosis ,General Biochemistry, Genetics and Molecular Biology ,Retrospective Studies ,Research Article - Abstract
Background/Aim: To clarify the clinical significance of measuring the mean corpuscular volume (MCV) of red blood cells before applying neoadjuvant chemotherapy (NAC) in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who will receive NAC followed by curative resection. Patients and Methods: We retrospectively investigated 169 eligible patients at the Kanagawa Cancer Center between 2011-2018. The patients were divided into high and low-MCV groups. The cutoff value of the MCV was determined by the maximum χ(2) statistic value on the log-rank test and was set at 92.8 fl. Clinicopathological features and outcomes were compared between the two groups. Results: There was no significant association between the MCV and clinicopathological features. Both five-year recurrence-free survival (RFS) and overall survival (OS) in the high-MCV group were significantly poorer than those in the low-MCV group (RFS, p=0.026; OS, p=0.006). On multivariate analysis, a high-MCV was an independent predictive survival factor for RFS [hazard ratio (HR)=1.728; 95% confidence interval (CI)=1.033-2.891; p=0.037] and OS (HR=1.836; 95%CI=1.002-3.365; p=0.049). Conclusion: Measurement of the MCV before NAC may be a useful prognostic biomarker in patients with locally advanced ESCC who will receive NAC followed by curative resection.
- Published
- 2022
89. Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice
- Author
-
Norio Yukawa, Keisuke Kazama, Takashi Oshima, Maho Sato, Masakatsu Numata, Toru Aoyama, Manabu Shiozawa, Mamoru Uchiyama, Yasushi Rino, Nobuhiro Sugano, Hiroshi Tamagawa, and Sumito Sato
- Subjects
Oncology ,medicine.medical_specialty ,Organoplatinum Compounds ,Bevacizumab ,Colorectal cancer ,Leucovorin ,Irinotecan ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Clinical endpoint ,Humans ,Retrospective Studies ,FOLFOXIRI ,business.industry ,Hazard ratio ,Gastroenterology ,medicine.disease ,Oxaliplatin ,Fluorouracil ,Camptothecin ,Colorectal Neoplasms ,business ,medicine.drug - Abstract
Purpose The efficacy of fluorouracil + oxaliplatin + irinotecan with bevacizumab (FOLFOXIRI + BV) has been verified for metastatic colorectal cancer (mCRC). In clinical practice, the original (O-FOLFOXIRI + BV) and modified dose settings (M-FOLFOXIRI + BV) are adopted for Asian patients. We aimed to compare the real-world efficacy and safety of these two regimens. Methods This retrospective cohort study reviewed clinical data of all consecutive mCRC patients treated with FOLFOXIRI + BV at a cancer centre in Japan. One hundred patients were divided into two groups: one that received O-FOLFOXIRI + BV (group O, n = 30) and another that received M-FOLFOXIRI + BV (group M, n = 70). Progression-free survival (PFS) was set as the primary endpoint, with overall survival (OS), overall response rate (ORR), and safety as secondary endpoints. Results PFS was superior in group M (median PFS; 8.7 vs. 11.5 months, P = 0.098). The use of O-FOLFOXIRI + BV emerged as an independent risk factor of poor PFS (hazard ratio = 2.155, P = 0.012). Both ORR (43.3 vs. 65.7%, P = 0.047) and OS (median OS; 17.9 vs. 27.0 months, P = 0.127) were more favourable in group M. Grade ≥ 3 adverse events were more frequently observed in group O (90 vs. 74.3%, P = 0.108), whereas dose intensity was higher in group M because a shorter duration was required for cytotoxic drug administration (2.9 vs. 2.6 weeks/course, P = 0.051) in the induction term. Conclusion We found that M-FOLFOXIRI + BV had more favourable efficacy and safety than O-FOLFOXIRI + BV, which may be a better fit for Asian patients and can be potentially used as an alternative for upfront chemotherapy for mCRC.
- Published
- 2021
90. Reference-Free Deterministic Calibration of Pipelined ADC.
- Author
-
Takashi Oshima and Taizo Yamawaki
- Published
- 2015
- Full Text
- View/download PDF
91. A CT 2–2 MASH ΔΣ ADC With Multi-Rate LMS-Based Background Calibration and Input-Insensitive Quantization-Error Extraction
- Author
-
Raed Alsubaie, Atsushi Ochi, Mitsuya Fukazawa, Masaki Fujiwara, Katsuki Tateyama, Tetsuo Matsui, and Takashi Oshima
- Subjects
CMOS ,Transmission (telecommunications) ,Computer science ,Modulation ,Dynamic range ,Distortion ,Bandwidth (signal processing) ,Hardware_INTEGRATEDCIRCUITS ,Electronic engineering ,Figure of merit ,Filter (signal processing) ,Electrical and Electronic Engineering - Abstract
This article presents a continuous-time (CT) multistage noise-shaping (MASH) delta–sigma ( $\Delta \Sigma$ ) analog-to-digital converter (ADC) with enhanced tolerance to temperature and operating-frequency variations through on-chip multi-rate (MR) background calibration based on the least-mean-square (LMS) algorithm. The proposed digital calibration, which combines MR operation, post-conditioners, and pseudorandom-noise injection at the quantizer input, efficiently and accurately matches digital transfer functions to the corresponding analog ones for cancellation of quantization error. The first modulator in the proposed MASH ADC considers sufficient quantizer delay and reduces input-signal leakage into the second modulator to enable successful quantization-error transmission while minimizing distortion in the second stage, which cannot be tolerated in the case of calibrated digital noise-cancellation filter. A CT 2–2 MASH $\Delta \Sigma $ ADC prototype fabricated in 40-nm CMOS achieves the dynamic range (DR) of 79 dB and the signal-to-noise and distortion ratio (SNDR) of 78.5 dB over an 8-MHz bandwidth with 7.3-mW analog power and 16-mW digital power, reaching Schreier figure of merit (FoMs) of 168.9 dB, and demonstrates conversion-accuracy robustness within 1-dB SNDR fluctuation for temperature variations from −40° to 125° and within 2-dB SNDR degradation for frequency variations of 20% range.
- Published
- 2021
92. Preoperative Pre-albumin Concentration as a Predictor of Short-term Outcomes in Elderly Patients With Colorectal Cancer
- Author
-
Yosuke Atsumi, Suguru Nukada, Manabu Shiozawa, Takashi Oshima, Masakatsu Numata, Hiroshi Tamagawa, Kenta Iguchi, Sumito Sato, Kuniya Tanaka, Yasushi Rino, and Keisuke Kazama
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Colorectal cancer ,Nutritional Status ,Pre albumin ,Elderly persons ,Risk Factors ,Albumins ,Internal medicine ,Preoperative Care ,Biomarkers, Tumor ,Humans ,Medicine ,Risk factor ,Retrospective Studies ,Aged, 80 and over ,Univariate analysis ,business.industry ,General Medicine ,Length of Stay ,Prognosis ,medicine.disease ,Confidence interval ,Colorectal surgery ,Survival Rate ,Oncology ,Female ,Colorectal Neoplasms ,business ,Colorectal Surgery ,Follow-Up Studies - Abstract
Background/aim Population aging results in increasing numbers of elderly persons undergoing surgery for colorectal cancer. We sought to identify objective preoperative indicators of outcomes, with a view toward development of safe, effective treatments for such patients. Patients and methods The study included 99 patients aged 80 years or more, who were treated surgically for stage I- III colorectal cancer. Preoperative nutritional status was compared retrospectively between those who suffered postoperative complications (n=40) and those who did not (n=59). Results Univariate analysis revealed low prealbumin (PreAlb) concentration (p=0.032) and low platelet-to-lymphocyte ratio (p=0.116) as risk factors for postoperative complications. Multivariate analysis showed preoperative PreAlb concentration to be an independent risk factor (OR=0.884; 95% confidence interval=0.791-0.989; p=0.024) associated with postoperative length of hospital stay (coef.=-0.336, p=0.002). Conclusion PreAlb, a rapid turnover protein, shows promise as a simple predictor of postoperative complications in elderly patients treated for colorectal surgery.
- Published
- 2021
93. Clinical Significance of Chemokine Receptor CXCR4 and CCR7 mRNA Expression in Patients With Colorectal Cancer
- Author
-
Toru Aoyama, Masakatsu Numata, Hayato Watanabe, Yukihiko Hiroshima, Naoto Yamamoto, Itaru Hashimoto, Hiroshi Saeki, Manabu Shiozawa, Kazuki Kano, Takanobu Yamada, Takashi Oshima, Yayoi Kimura, Sumito Sato, Norio Yukawa, Shinsuke Nagasawa, Soichiro Morinaga, Yohei Miyagi, Yasushi Rino, Munetaka Masuda, Kazuhito Tsuchida, Hiroshi Tamagawa, and Takashi Ogata
- Subjects
Male ,Receptors, CCR7 ,Receptors, CXCR4 ,Cancer Research ,Colorectal cancer ,Rectum ,C-C chemokine receptor type 7 ,CXCR4 ,Metastasis ,Chemokine receptor ,Biomarkers, Tumor ,medicine ,Humans ,Clinical significance ,Aged ,business.industry ,Gene Expression Profiling ,Cancer ,hemic and immune systems ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Survival Analysis ,Tumor Burden ,Up-Regulation ,Gene Expression Regulation, Neoplastic ,Treatment Outcome ,medicine.anatomical_structure ,Oncology ,Cancer research ,Female ,Colorectal Neoplasms ,business - Abstract
Background/aim The chemokine receptors C-X-C chemokine receptor type 4 (CXCR4) and C-C chemokine receptor type 7 (CCR7) play an important role in the invasion and metastasis of cancer. This study investigated the relationship between relative expression of CXCR4 and CCR7 mRNA, clinicopathological factors, and outcomes in patients with colorectal cancer (CRC). Patients and methods We studied 202 patients who underwent surgery for CRC. The expression levels of CXCR4 and CCR7 mRNA in cancerous tissue were measured using quantitative real-time reverse-transcriptase polymerase chain reaction. Results High CCR7 mRNA expression levels in CRC tissues were positively associated with tumour size and were more frequently associated with cancer of the rectum than of the colon. Moreover, outcomes were significantly poorer in patients with high CCR7 mRNA expression than in those with low expression. On multivariate Cox regression analysis, a higher CCR7 mRNA expression level was a significant independent predictor of poorer overall survival in patients with CRC. Conclusion Overexpression of CCR7 mRNA may be a useful independent prognostic factor in patients with CRC.
- Published
- 2021
94. Clinical Significance of
- Author
-
Hideaki, Suematsu, Kentaro, Sakamaki, Naohide, Oue, Yukihiko, Hiroshima, Yayoi, Kimura, Shizune, Onuma, Itaru, Hashimoto, Shinsuke, Nagasawa, Toru, Aoyama, Takanobu, Yamada, Hiroshi, Tamagawa, Takashi, Ogata, Yasushi, Rino, Munetaka, Masuda, Wataru, Yasui, Yohei, Miyagi, and Takashi, Oshima
- Subjects
Stomach Neoplasms ,Lymphatic Metastasis ,Multivariate Analysis ,Humans ,Neoplasms, Second Primary ,Peptide Hydrolases - Abstract
SEC11A gene encodes the SPC18 protein, which has been implicated in tumour progression by inducing the secretion of various growth factors. We investigated the clinical significance of SEC11A expression in gastric cancer (GC) tissues in patients with locally advanced gastric cancer (LAGC) after curative resection.We estimated SEC11A expression in cancer tissues from 253 pStage II/III GC patients who underwent curative resection using quantitative polymerase chain reaction (PCR) and investigated the relationship of SEC11A expression with clinicopathological factors and survival.SEC11A expression was significantly related to serosal invasion, lymph node metastasis, lymphatic invasion, and pathological stage. The high-SEC11A expression group had a significantly lower survival rate than the low group (5-year survival 52.3% vs. 75.9%; p0.005). Furthermore, in multivariate analysis, high-SEC11A expression was an independent factor of poor survival (hazard ratio, 2.010; 95% confidence interval=1.303-3.100; p=0.002).SEC11A expression in cancer tissue may be a useful prognostic marker in patients with LAGC after curative resection.
- Published
- 2022
95. Clinical Effect of the C-Reactive Protein to Serum Albumin Ratio in Patients with Metastatic Gastric or Gastroesophageal Junction Cancer Treated with Trifluridine/Tipiracil
- Author
-
Itaru Hashimoto, Kazuki Kano, Shizune Onuma, Hideaki Suematsu, Shinsuke Nagasawa, Kyohei Kanematsu, Kyoko Furusawa, Tomomi Hamaguchi, Mamoru Watanabe, Kei Hayashi, Mitsuhiro Furuta, Yasuhiro Inokuchi, Nozomu Machida, Toru Aoyama, Takanobu Yamada, Yasushi Rino, Takashi Ogata, and Takashi Oshima
- Subjects
C-reactive protein to serum albumin ratio ,gastric cancer ,gastroesophageal junction cancer ,trifluridine/tipiracil ,Medicine (miscellaneous) - Abstract
Trifluridine/tipiracil (FTD/TPI) is an oral anticancer agent used as a third- or later-line treatment for patients with metastatic gastric cancer/gastroesophageal junction cancer (mGC/GEJC). The C-reactive protein-to-serum albumin ratio (CAR) is an inflammation-based prognostic marker in gastric cancer. This retrospective study evaluated CAR’s clinical significance as a prognostic factor in 64 patients with mGC/GEJC administered FTD/TPI as a third- or later-line therapy. Patients were categorized into high- and low-CAR groups based on pre-treatment blood data. This study evaluated associations between CAR and overall survival (OS), progression-free survival (PFS), clinicopathological features, treatment efficacy, and adverse events. The high-CAR group had significantly worse Eastern Cooperative Oncology Group performance status, a higher prevalence of patients administered with a single course of FTD/TPI, and a higher rate of patients not administered chemotherapy after FTD/TPI therapy than the low-CAR group. Median OS and PFS were significantly poorer in the high-CAR group than in the low-CAR group (113 vs. 399 days; p < 0.001 and 39 vs. 112 days; p < 0.001, respectively). In multivariate analysis, high CAR was an independent prognostic factor for OS and PFS. The overall response rate was not significantly different between the high- and low-CAR groups. Regarding adverse events, the high-CAR group had a significantly lower incidence of neutropenia and a higher incidence of fatigue than the low-CAR group. Therefore, CAR may be a potentially useful prognostic factor for patients with mGC/GEJC treated with FTD/TPI as third- or later-line chemotherapy.
- Published
- 2023
96. 23-mW 50-MS/s 10-bit Pipeline A/D converter with Nonlinear LMS Foreground Calibration.
- Author
-
Takashi Oshima, Tomomi Takahashi, and Taizo Yamawaki
- Published
- 2009
- Full Text
- View/download PDF
97. A Fully Integrated SAR ADC Using Digital Correction Technique for Triple-Mode Mobile Transceiver.
- Author
-
Hideo Nakane, Ryuichi Ujiie, Takashi Oshima, Takaya Yamamoto, Keisuke Kimura, Yuichi Okuda, Kosuke Tsuiji, and Tatsuji Matsuura
- Published
- 2014
- Full Text
- View/download PDF
98. Clinical Significance of PLA2G2A Expression in Gastric Cancer Patients who Receive Gastrectomy and Adjuvant S-1
- Author
-
Hiroshi Tamagawa, Kentaro Sakamaki, Munetaka Masuda, Itaru Hashimoto, Yayoi Kimura, Yasushi Rino, Takashi Oshima, Yukihiko Hiroshima, Soichiro Morinaga, Hayato Watanabe, Shinsuke Hatori, Kazuki Kano, Naoto Yamamoto, Toru Aoyama, Masakatsu Numata, Manabu Shizawa, Keisuke Komori, Takashi Ogata, Hiroshi Saeki, Yohei Miyagi, Hirohito Fujikawa, Norio Yukawa, Takanobu Yamada, and Takehiko Yokohori
- Subjects
Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,business.industry ,medicine.medical_treatment ,Hazard ratio ,Cancer ,General Medicine ,medicine.disease ,Gastroenterology ,Confidence interval ,Real-time polymerase chain reaction ,Oncology ,Internal medicine ,Medicine ,Gastrectomy ,Clinical significance ,business ,Adjuvant - Abstract
Background/aim This study aimed to evaluate the prognostic significance of PLA2G2A expression in patients with locally advanced gastric cancer (GC). Patients and methods PLA2G2A expression levels in cancerous tissue specimens and adjacent normal mucosa obtained from 134 patients with stage II/III GC who received adjuvant chemotherapy with S-1 after curative resection were measured using real-time quantitative polymerase chain reaction. Subsequently, the associations of PLA2G2A expression with clinicopathological features and survival were evaluated. Results No association was observed between clinicopathological features and PLA2G2A expression levels. Overall survival was significantly longer in patients with high PLA2G2A expression levels (p=0.022). Multivariate analysis revealed that PLA2G2A expression was a significant, independent prognostic factor (hazard ratio=0.136; 95% confidence interval=0.0185-0.992; p=0.049). Conclusion PLA2G2A mRNA expression may serve as a useful prognostic marker in patients with locally advanced GC who receive curative surgery and adjuvant chemotherapy with S-1.
- Published
- 2021
99. The Prognostic Value of Lymph Node Ratio in Locally Advanced Esophageal Cancer Patients Who Received Neoadjuvant Chemotherapy
- Author
-
Yasushi Rino, Munetaka Masuda, Takanobu Yamada, Kazuki Kano, Kosuke Takahashi, Takashi Oshima, Hiroshi Tamagawa, Keisuke Komori, Takashi Ogata, Hirohito Fujikawa, Norio Yukawa, Hayato Watanabe, Masakatsu Numata, and Toru Aoyama
- Subjects
Oncology ,medicine.medical_specialty ,Esophageal Neoplasms ,medicine.medical_treatment ,03 medical and health sciences ,0302 clinical medicine ,Surgical oncology ,Internal medicine ,medicine ,Humans ,Risk factor ,Lymph node ,Survival rate ,Neoplasm Staging ,Retrospective Studies ,Chemotherapy ,Receiver operating characteristic ,business.industry ,Hazard ratio ,Esophageal cancer ,Prognosis ,medicine.disease ,Neoadjuvant Therapy ,medicine.anatomical_structure ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Lymph Node Excision ,030211 gastroenterology & hepatology ,Surgery ,Esophageal Squamous Cell Carcinoma ,Lymph Nodes ,business ,Lymph Node Ratio - Abstract
The lymph node (LN) ratio (LNR) has been proposed as a sensitive prognosticator in patients with esophageal squamous cell carcinoma (ESCC), especially when the number of LNs harvested is insufficient. We investigated the association between the LNR and survival in patients with locally advanced ESCC who received neoadjuvant chemotherapy (NAC) and explored whether the LNR is a prognosticator in these patients when stratified by their response to NAC. We retrospectively reviewed 199 locally advanced ESCC patients who received curative resection after NAC between January 2011 and December 2019. The predictive accuracy of the adjusted X-tile cut-off values for LNR of 0 and 0.13 was compared with that in the Union for International Cancer Control pathological N (UICC pN) categories. The association between survival rate and clinicopathological features was examined. Multivariate analysis identified that the LNR was an independent risk factor for recurrence-free survival [RFS; hazard ratio (HR) 6.917, p
- Published
- 2021
100. Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
- Author
-
Takanobu Yamada, Munetaka Masuda, Kosuke Takahashi, Yasuhiro Inokuchi, Keisuke Komori, Takashi Ogata, Kazuki Kano, Hayato Watanabe, Nozomu Machida, Hirohito Fujikawa, Yasushi Rino, Takashi Oshima, and Tomoyuki Yokose
- Subjects
nivolumab ,Chemotherapy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,gastric cancer ,Single Case ,Gastroenterology ,Cancer ,RC799-869 ,Diseases of the digestive system. Gastroenterology ,medicine.disease ,Primary tumor ,Metastasis ,Surgery ,Ramucirumab ,Capecitabine ,conversion surgery ,medicine ,Adenocarcinoma ,Nivolumab ,business ,medicine.drug - Abstract
There are few reports of conversion surgery (CS) after nivolumab monotherapy because it is considered as a third-line standard chemotherapy for unresectable or recurrent gastric cancer. Here, we report a rare case of stage IV gastric cancer effectively treated with CS after nivolumab monotherapy as a third-line chemotherapy. A 73-year-old man was referred to our hospital with loss of appetite and abdominal discomfort. Stage IV gastric cancer with liver metastasis was diagnosed via upper gastrointestinal endoscopy and CT. Twelve courses of capecitabine, cisplatin, and trastuzumab were administered as the first-line treatment, 25 courses of paclitaxel plus ramucirumab as the second-line treatment, and 31 courses of nivolumab monotherapy as the third-line treatment. After 31 courses of nivolumab monotherapy, CT showed that the primary tumor shrank with no liver metastasis or ascites. Diagnostic laparoscopy was performed with no peritoneal dissemination (P0), and the peritoneal lavage cytology was negative (CY0). CS was performed with total gastrectomy and D2 lymph node dissection (R0 resection). The pathological diagnosis was U, Ant-Less, Type 2, 70 × 63 mm, poorly differentiated adenocarcinoma (ypT3N0M0 ypStage IIA). R0 resection was performed, and the histological response was grade 1a. The patient did not show recurrence for 9 months after CS.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.